339 related articles for article (PubMed ID: 14702141)
1. The adenosine A(2A) receptor as an attractive target for Parkinson's disease treatment.
Chen JF
Drug News Perspect; 2003 Nov; 16(9):597-604. PubMed ID: 14702141
[TBL] [Abstract][Full Text] [Related]
2. Dual-target-directed drugs that block monoamine oxidase B and adenosine A(2A) receptors for Parkinson's disease.
Petzer JP; Castagnoli N; Schwarzschild MA; Chen JF; Van der Schyf CJ
Neurotherapeutics; 2009 Jan; 6(1):141-51. PubMed ID: 19110205
[TBL] [Abstract][Full Text] [Related]
3. [Is the inhibition of adenosine A(2A) receptors an efficient way of Parkinson's disease treatment?].
Ceiślak M; Komoszyński M
Neurol Neurochir Pol; 2006; 40(3):219-26. PubMed ID: 16794962
[TBL] [Abstract][Full Text] [Related]
4. Adenosine A2A receptors in neuroadaptation to repeated dopaminergic stimulation: implications for the treatment of dyskinesias in Parkinson's disease.
Chen JF; Fredduzzi S; Bastia E; Yu L; Moratalla R; Ongini E; Schwarzschild MA
Neurology; 2003 Dec; 61(11 Suppl 6):S74-81. PubMed ID: 14663016
[TBL] [Abstract][Full Text] [Related]
5. Can adenosine A
Kanda T; Jenner P
Parkinsonism Relat Disord; 2020 Nov; 80 Suppl 1():S21-S27. PubMed ID: 33349576
[TBL] [Abstract][Full Text] [Related]
6. Synergistic effects of adenosine A2A antagonist and L-DOPA on rotational behaviors in 6-hydroxydopamine-induced hemi-Parkinsonian mouse model.
Matsuya T; Takuma K; Sato K; Asai M; Murakami Y; Miyoshi S; Noda A; Nagai T; Mizoguchi H; Nishimura S; Yamada K
J Pharmacol Sci; 2007 Mar; 103(3):329-32. PubMed ID: 17341841
[TBL] [Abstract][Full Text] [Related]
7. Do caffeine and more selective adenosine A
Chen JF; Schwarzschild MA
Parkinsonism Relat Disord; 2020 Nov; 80 Suppl 1(Suppl 1):S45-S53. PubMed ID: 33349580
[TBL] [Abstract][Full Text] [Related]
8. A new ethyladenine antagonist of adenosine A(2A) receptors: behavioral and biochemical characterization as an antiparkinsonian drug.
Pinna A; Tronci E; Schintu N; Simola N; Volpini R; Pontis S; Cristalli G; Morelli M
Neuropharmacology; 2010 Mar; 58(3):613-23. PubMed ID: 19951715
[TBL] [Abstract][Full Text] [Related]
9. Adenosine A2A receptor antagonists and Parkinson's disease: state of the art and future directions.
Simola N; Morelli M; Pinna A
Curr Pharm Des; 2008; 14(15):1475-89. PubMed ID: 18537671
[TBL] [Abstract][Full Text] [Related]
10. New therapies for the treatment of Parkinson's disease: adenosine A2A receptor antagonists.
Pinna A; Wardas J; Simola N; Morelli M
Life Sci; 2005 Nov; 77(26):3259-67. PubMed ID: 15979104
[TBL] [Abstract][Full Text] [Related]
11. Targeting adenosine A2A receptors in Parkinson's disease.
Schwarzschild MA; Agnati L; Fuxe K; Chen JF; Morelli M
Trends Neurosci; 2006 Nov; 29(11):647-54. PubMed ID: 17030429
[TBL] [Abstract][Full Text] [Related]
12. L-DOPA-treatment in primates disrupts the expression of A(2A) adenosine-CB(1) cannabinoid-D(2) dopamine receptor heteromers in the caudate nucleus.
Bonaventura J; Rico AJ; Moreno E; Sierra S; Sánchez M; Luquin N; Farré D; Müller CE; Martínez-Pinilla E; Cortés A; Mallol J; Armentero MT; Pinna A; Canela EI; Lluís C; McCormick PJ; Lanciego JL; Casadó V; Franco R
Neuropharmacology; 2014 Apr; 79():90-100. PubMed ID: 24230991
[TBL] [Abstract][Full Text] [Related]
13. Istradefylline, a novel adenosine A2A receptor antagonist, for the treatment of Parkinson's disease.
Jenner P
Expert Opin Investig Drugs; 2005 Jun; 14(6):729-38. PubMed ID: 16004599
[TBL] [Abstract][Full Text] [Related]
14. Progress in pursuit of therapeutic A2A antagonists: the adenosine A2A receptor selective antagonist KW6002: research and development toward a novel nondopaminergic therapy for Parkinson's disease.
Kase H; Aoyama S; Ichimura M; Ikeda K; Ishii A; Kanda T; Koga K; Koike N; Kurokawa M; Kuwana Y; Mori A; Nakamura J; Nonaka H; Ochi M; Saki M; Shimada J; Shindou T; Shiozaki S; Suzuki F; Takeda M; Yanagawa K; Richardson PJ; Jenner P; Bedard P; Borrelli E; Hauser RA; Chase TN;
Neurology; 2003 Dec; 61(11 Suppl 6):S97-100. PubMed ID: 14663020
[TBL] [Abstract][Full Text] [Related]
15. Novel neuroprotection by caffeine and adenosine A(2A) receptor antagonists in animal models of Parkinson's disease.
Kalda A; Yu L; Oztas E; Chen JF
J Neurol Sci; 2006 Oct; 248(1-2):9-15. PubMed ID: 16806272
[TBL] [Abstract][Full Text] [Related]
16. Adenosine A2A antagonists: potential preventive and palliative treatment for Parkinson's disease.
Morelli M
Exp Neurol; 2003 Nov; 184(1):20-3. PubMed ID: 14637073
[No Abstract] [Full Text] [Related]
17. Neuroprotective effect of L-DOPA co-administered with the adenosine A2A receptor agonist CGS 21680 in an animal model of Parkinson's disease.
Agnati LF; Leo G; Vergoni AV; Martínez E; Hockemeyer J; Lluis C; Franco R; Fuxe K; Ferré S
Brain Res Bull; 2004 Aug; 64(2):155-64. PubMed ID: 15342103
[TBL] [Abstract][Full Text] [Related]
18. Adenosine A2A and dopamine receptor interactions in basal ganglia of dopamine denervated rats.
Carta AR; Pinna A; Tronci E; Morelli M
Neurology; 2003 Dec; 61(11 Suppl 6):S39-43. PubMed ID: 14663008
[TBL] [Abstract][Full Text] [Related]
19. L-DOPA disrupts adenosine A(2A)-cannabinoid CB(1)-dopamine D(2) receptor heteromer cross-talk in the striatum of hemiparkinsonian rats: biochemical and behavioral studies.
Pinna A; Bonaventura J; Farré D; Sánchez M; Simola N; Mallol J; Lluís C; Costa G; Baqi Y; Müller CE; Cortés A; McCormick P; Canela EI; Martínez-Pinilla E; Lanciego JL; Casadó V; Armentero MT; Franco R
Exp Neurol; 2014 Mar; 253():180-91. PubMed ID: 24412491
[TBL] [Abstract][Full Text] [Related]
20. Pathophysiological roles for purines: adenosine, caffeine and urate.
Morelli M; Carta AR; Kachroo A; Schwarzschild MA
Prog Brain Res; 2010; 183():183-208. PubMed ID: 20696321
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]